Accueil   Diary - News   All news Valneva announces signing license agreement with China

Valneva announces signing license agreement with China

Valneva announces signing of an exclusive license agreement on EB66® Cell Line for Human and Veterinary Vaccines in People’s Republic of China

 

  • The partner Jianshun Biosciences Ltd is granted exclusive rights to commercialize the EB66® cell line in People’s Republic of China only
  • Valneva receives EUR 2.5 million upfront payment and is entitled to further annual license fees and royalties
  • China’s Human vaccine market reached nearly EUR 2 billion (RMB 13.7 billion) in 20121, with an average growth rate in the range of 16%-18% expected between 2014 and 2018
  • Valneva and Jianshun Biosciences Ltd see a significant business opportunity arising from the growth of the vaccine market and the technological shift of the Chinese vaccine manufacturing industry, which will benefit from the EB66® cell line as a modern cell-culture based production system.

 

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree